Lund­beck tries to rush its FDA-ap­proved mi­graine drug to Chi­na but fails PhI­II tri­al

Sales of Lund­beck’s CGRP in­hibitor Vyep­ti, first ap­proved in the US in 2020 and ear­li­er this year in Eu­rope, dou­bled to more than $50 mil­lion in the first half of 2022. But the up-and-com­ing mi­graine drug faces a crowd­ed field and the com­pa­ny dis­closed Thurs­day that it failed to beat out place­bo in a small­er Phase III tri­al based in Asia.

The set­back may not mean much in terms of in­tro­duc­ing the drug in­to Asian coun­tries more wide­ly, but it’s a set­back nonethe­less.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER